ATE394122T1 - Hemmung des cd95 liganden/rezeptor-systems zur behandlung von neurologischen erkrankungen und verletzungen - Google Patents
Hemmung des cd95 liganden/rezeptor-systems zur behandlung von neurologischen erkrankungen und verletzungenInfo
- Publication number
- ATE394122T1 ATE394122T1 AT04709605T AT04709605T ATE394122T1 AT E394122 T1 ATE394122 T1 AT E394122T1 AT 04709605 T AT04709605 T AT 04709605T AT 04709605 T AT04709605 T AT 04709605T AT E394122 T1 ATE394122 T1 AT E394122T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- injuries
- ligand
- inhibition
- receptor system
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03003426A EP1447093A1 (de) | 2003-02-14 | 2003-02-14 | Inhibition des CD95 Ligand/Rezeptorsystems zur Behandlung neurologischer Störungen und Verletzungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE394122T1 true ATE394122T1 (de) | 2008-05-15 |
Family
ID=32668981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04709605T ATE394122T1 (de) | 2003-02-14 | 2004-02-10 | Hemmung des cd95 liganden/rezeptor-systems zur behandlung von neurologischen erkrankungen und verletzungen |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7935339B2 (de) |
| EP (2) | EP1447093A1 (de) |
| JP (1) | JP4800920B2 (de) |
| AT (1) | ATE394122T1 (de) |
| AU (1) | AU2004212308C1 (de) |
| CA (1) | CA2514794C (de) |
| DE (1) | DE602004013540D1 (de) |
| DK (1) | DK1592446T3 (de) |
| ES (1) | ES2301966T3 (de) |
| WO (1) | WO2004071528A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007336770A1 (en) | 2006-12-22 | 2008-07-03 | Genentech, Inc. | DR6 antibodies inhibiting the binding of DR6 to APP, and uses thereof in treating neurological disorders |
| US9309320B2 (en) | 2006-12-28 | 2016-04-12 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo |
| US20110189194A1 (en) * | 2008-07-14 | 2011-08-04 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Use of cd95 inhibitors for the treatment of inflammatory disorders |
| EP2376120A2 (de) | 2008-11-25 | 2011-10-19 | Biogen Idec MA Inc. | Verwendung von dr6- und p75-antagonisten zur förderung des überlebens von zellen des nervensystems |
| BR112012009997A2 (pt) | 2009-11-12 | 2019-09-24 | Genentech Inc | ''método para aumentar a densidade de espinhas dentriticas nos neurônios de um paciente com um distúrbios cognitivo ou psiquiatrico,método de manutenção da cognição em um sujeito durante o processo de envelhecimento,uso de um antagonista de dr6 na preparação de um medicamento para uso em um paciente com um disturbio cognitivo uo psiquíatrico e uso de um antagonista de p75 na preparação de um medicamento para uso em um paciente com um distúrbio cognitivo ou psiquiátrico'' |
| KR102908806B1 (ko) | 2015-10-22 | 2026-01-07 | 주노 테라퓨틱스 게엠베하 | 세포의 배양 방법 및 이를 위한 키트와 장치 |
| CN111546719B (zh) * | 2020-04-21 | 2022-07-01 | 中国船舶重工集团公司第七二五研究所 | 一种磁性宽频带电磁吸波超材料 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4447484C2 (de) * | 1994-04-08 | 1997-07-17 | Deutsches Krebsforsch | Mittel zur Hemmung von Apoptose |
| NZ311174A (en) | 1995-06-30 | 1999-04-29 | Mochida Pharm Co Ltd | Anti-fas ligand antibody which suppresses fas ligand-induced apoptosis in cells and method of assaying a fas ligand using the anti-fas ligand antibody |
| ATE273713T1 (de) * | 1996-10-31 | 2004-09-15 | Mochida Pharm Co Ltd | Fas-antagonist für die prophylaxe oder therapie von gvhd |
| US6001962A (en) * | 1996-11-15 | 1999-12-14 | The Regents Of The University Of California | Modified Fas ligands |
| WO1999014330A1 (en) * | 1997-09-18 | 1999-03-25 | Genentech, Inc. | DcR3 POLYPEPTIDE, A TNFR HOMOLOG |
| ES2291197T3 (es) * | 1999-03-30 | 2008-03-01 | Eli Lilly And Company | Analogos de flint resistentes a proteasas. |
| WO2000072707A1 (en) * | 1999-05-26 | 2000-12-07 | Ikuo Toratani | Clothing such as shorts and bathing suit |
| DE19959049A1 (de) | 1999-12-07 | 2001-06-28 | Deutsches Krebsforsch | Kombination von Verbindungen, welche die biologischen Wirkungen von TNF-alpha und CD95L hemmen |
| US6689784B2 (en) * | 2000-03-29 | 2004-02-10 | Vertex Pharmaceuticals Incorporated | Carbamate caspase inhibitors and uses thereof |
| KR100932577B1 (ko) * | 2001-05-18 | 2009-12-17 | 기린 홀딩스 가부시키가이샤 | 항 trail-r 항체 |
-
2003
- 2003-02-14 EP EP03003426A patent/EP1447093A1/de not_active Withdrawn
-
2004
- 2004-02-10 ES ES04709605T patent/ES2301966T3/es not_active Expired - Lifetime
- 2004-02-10 EP EP04709605A patent/EP1592446B1/de not_active Expired - Lifetime
- 2004-02-10 AT AT04709605T patent/ATE394122T1/de not_active IP Right Cessation
- 2004-02-10 US US10/545,231 patent/US7935339B2/en not_active Expired - Fee Related
- 2004-02-10 DK DK04709605T patent/DK1592446T3/da active
- 2004-02-10 CA CA2514794A patent/CA2514794C/en not_active Expired - Fee Related
- 2004-02-10 WO PCT/EP2004/001233 patent/WO2004071528A1/en not_active Ceased
- 2004-02-10 JP JP2006501795A patent/JP4800920B2/ja not_active Expired - Fee Related
- 2004-02-10 DE DE602004013540T patent/DE602004013540D1/de not_active Expired - Lifetime
- 2004-02-10 AU AU2004212308A patent/AU2004212308C1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP1592446B1 (de) | 2008-05-07 |
| WO2004071528A1 (en) | 2004-08-26 |
| AU2004212308C1 (en) | 2009-10-29 |
| US7935339B2 (en) | 2011-05-03 |
| DK1592446T3 (da) | 2008-09-01 |
| US20060234968A1 (en) | 2006-10-19 |
| ES2301966T3 (es) | 2008-07-01 |
| AU2004212308A1 (en) | 2004-08-26 |
| JP2006517559A (ja) | 2006-07-27 |
| JP4800920B2 (ja) | 2011-10-26 |
| CA2514794C (en) | 2013-05-28 |
| CA2514794A1 (en) | 2004-08-26 |
| DE602004013540D1 (de) | 2008-06-19 |
| EP1447093A1 (de) | 2004-08-18 |
| AU2004212308B2 (en) | 2009-05-21 |
| EP1592446A1 (de) | 2005-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE427759T1 (de) | Behandlung von fettsucht und verbundenen erkrankungen | |
| DE602004020072D1 (de) | 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen | |
| ATE445415T1 (de) | Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung | |
| ATE554756T1 (de) | Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen | |
| ATE440866T1 (de) | Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten | |
| ATE413385T1 (de) | Zur behandlung von schmerzen geeignete therapeutische mittel | |
| ATE376828T1 (de) | Verwendung von rotigotin zur behandlung und prävention des parkinson-plus-syndroms | |
| IL219857A0 (en) | Mitotic kinesin inhibitors, pharmaceutical compositions comprising them, uses thereof in the manufacture of a medicament for the treatment of disease or disorder in a human or animal that can be treated by inhibiting mitosis | |
| ATE555803T1 (de) | Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen | |
| ATE415968T1 (de) | 3,11b-cis-dihydrotetrabanezin zur behandlung von schizophrenie und anderen psychosen | |
| TW200505904A (en) | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | |
| ATE456955T1 (de) | Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen | |
| DE60231107D1 (de) | Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems | |
| DE50109156D1 (de) | Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd | |
| DE60008753D1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
| DE602005025941D1 (de) | Alpha-Aminoamid-Derivate zur Behandlung von Suchtstörungen | |
| ATE446754T1 (de) | Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten | |
| NO20054913D0 (no) | Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser | |
| DE60219687D1 (de) | Aroylpyrrolheteroeryl und methanole zur behandlung von störungen des zentralnervensystems | |
| DE602004013540D1 (de) | Hemmung des cd95 liganden/rezeptor-systems zur behandlung von neurologischen erkrankungen und verletzungen | |
| NO20055563L (no) | Midler for behandlingen av lavere abdominale lidelser | |
| TW200735868A (en) | Compositions and methods for treating CNS disorders | |
| ATE494903T1 (de) | Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden | |
| DE60108130D1 (de) | Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten | |
| ATE420071T1 (de) | 2- (1h-indolylsulfanyl) -arylaminderivate zur verwendung bei der behandlung von affektiven psychosen, schmerzen, dem hyperkinetischen syndrom des kindesalters (adhd) und stressharninkontinenz |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1592446 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |